We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
La Jolla Pharmaceutical Company was granted Breakthrough Therapy designation by the FDA for the New Investigational Drug Product, LJPC-0118, for the treatment of severe malaria.
The FDA’s Breakthrough Device designation is granted for technologies that have the potential to provide for more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases